Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 23, 2023

Extended-Interval Dosing of Ocrelizumab Modifies the Repopulation of B Cells Without Altering the Clinical Efficacy in Patients With MS

Journal of Neuroinflammation


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Neuroinflammation
Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
J Neuroinflammation 2023 Sep 26;20(1)215, C Rodriguez-Mogeda, ZYGJ van Lierop, SMA van der Pol, L Coenen, L Hogenboom, A Kamermans, E Rodriguez, J van Horssen, ZLE van Kempen, BMJ Uitdehaag, CE Teunissen, ME Witte, J Killestein, HE de Vries

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading